EAPI Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Euroapi S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.54 |
| 52 Week High | €12.97 |
| 52 Week Low | €2.26 |
| Beta | 0.52 |
| 11 Month Change | 43.58% |
| 3 Month Change | 26.11% |
| 1 Year Change | -61.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -66.41% |
Recent News & Updates
Recent updates
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Jul 29
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 24Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
Apr 10Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
Mar 03Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Mar 02A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Dec 21Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
Aug 04Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Aug 02Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
Jun 16An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Jan 25Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 38% Above Its Share Price
Oct 15Statutory Profit Doesn't Reflect How Good Euroapi's (EPA:EAPI) Earnings Are
Sep 09Shareholder Returns
| EAPI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 8.3% | 1.1% | 1.6% |
| 1Y | -61.8% | -0.1% | 1.3% |
Return vs Industry: EAPI underperformed the French Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: EAPI underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: EAPI's share price has been volatile over the past 3 months.
Volatility Over Time: EAPI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3,329 | Ludwig De Mot | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. It provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. The company was incorporated in 2020 and is based in Paris, France.
Euroapi S.A. Fundamentals Summary
| EAPI fundamental statistics | |
|---|---|
| Market cap | €432.49m |
| Earnings (TTM) | -€287.30m |
| Revenue (TTM) | €971.30m |
0.4x
P/S Ratio-1.5x
P/E RatioIs EAPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAPI income statement (TTM) | |
|---|---|
| Revenue | €971.30m |
| Cost of Revenue | €805.80m |
| Gross Profit | €165.50m |
| Other Expenses | €452.80m |
| Earnings | -€287.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | -3.02 |
| Gross Margin | 17.04% |
| Net Profit Margin | -29.58% |
| Debt/Equity Ratio | 50.9% |
How did EAPI perform over the long term?
See historical performance and comparison